In the bio-tech market,
Kenvue Inc. (NYSE:KVUE) shares have seen diverse transaction activity. Investments LLC, Gradient Investments, SG Securities, among others, have reduced their Kenvue position. However, New Century Financial Group, GoalVest Advisory, Czech National Bank facilitated a surge in stocks. The stocks crossed the 4% yield mark, while future earnings uncertainty tagged along with Barclay's pessimistic forecast and Citigroup's lowered price target. Analysts estimate a decline in earnings. However, the declaration of
$0.205 quarterly dividend reflects strong portfolio performance. Kenvue's
financial update schedule for Q4, 2024, is due on February 6, 2025. Activist hedge funds have marked Kenvue as a key interest point. A buoyant intrinsic calculation suggests
under-valuation by 33%. Despite some disappointment from falling skin health sales and a lacklustre earnings report, Kenvue's favourable stance on
climate action stirred investor interest. The significant stake by Starboard Value also pushed Kenvue into the limelight. Overall, Kenvue managed to maintain relative strength in price performance with a rise to 82 RS rating and a 52-week high at $24.33.
Kenvue KVUE News Analytics from Thu, 25 Jul 2024 07:00:00 GMT to Sat, 25 Jan 2025 12:21:09 GMT -
Rating 2
- Innovation 5
- Information 8
- Rumor -3
